The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Myostatin and Sarcopenia: Opportunities and Challenges - A Mini-Review
Abstract
The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of myostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Myostatin is also expressed in adipose tissue and is inversely related to insulin resistance445.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [445]
In the citing paper
“Myostatin expression increases in skeletal muscle due to obesity and IR. Thus, it could favor the loss of skeletal muscle in SO [14, 61, 62].”
From The critical role of oxidative stress in sarcopenic obesity (2021) · cites this paper as [62]
In the citing paper
“Production of myostatin, a growth-inhibiting myokine, is upregulated in sarcopenia64, whereas that of muscle-mass-stimulating irisin seems to be downregulated65.”
From Sarcopenic obesity in older adults: a clinical overview (2024) · cites this paper as [64]
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Myostatin Inhibits Myoblast Differentiation by Down-regulating MyoD Expression
Langley, B., Thomas, M., Bishop, A., Sharma, M., Gilmour, S., & Kambadur, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204291200 · Cited by 908
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
REGULATION OF MUSCLE MASS BY MYOSTATIN
Lee, S.-J. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.135836 · Cited by 819
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
Smad2 and 3 transcription factors control muscle mass in adulthood
Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., & Sandri, M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00104.2009 · Cited by 517
Suppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505
Inhibition of myostatin in adult mice increases skeletal muscle mass and strength
Whittemore, L.-A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P., Knight, A., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02953-4 · Cited by 503
Research works printed but not linked: 1
- 10.1172/JCI13562 · doi:10.1172/jci13562 · Paper page
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Skeletal muscle performance and ageing
Tieland, M., Trouwborst, I., & Clark, B. C. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12238 · Cited by 904
“therapy for sarcopenia, which could affect skeletal muscle performance.(208)”
Sarcopenia: A Contemporary Health Problem among Older Adult Populations
Papadopoulou, S. (2020) · Nutrients · doi:10.3390/nu12051293 · Cited by 588
Sarcopenia: burden and challenges for public health
Beaudart, C., Rizzoli, R., Bruyère, O., Reginster, J.-Y., & Biver, E. (2014) · Archives of Public Health · doi:10.1186/2049-3258-72-45 · Cited by 495
“be the inhibition of myostatin, a regulator of muscle development and growth [59,60].”
BackgroundCai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Metadata
- Authors
- White, T. A., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Venue
- Gerontology
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 60
- Issue
- 4
- Pages
- 289-293
- ISSN
- 0304-324X (ISSN-L)
- 1423-0003
- OpenAlex
- W2006774297
- Cited by
- 191
- References
- 32
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 14 · 2023: 23 · 2022: 17 · 2021: 25 · 2020: 17 · 2019: 16 · 2018: 12 · 2017: 13 · 2016: 14 · 2015: 7 · 2014: 10
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Gerontology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Center for Cell Signaling in Gastroenterology, Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK084567)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- myostatin, sarcopenia, skeletal muscle atrophy, muscle strength, aging, myostatin inhibition, therapeutic target, clinical translation, muscle growth regulation
- MeSH terms
- Aged, Aging, Animals, Humans, Signal Transduction, Muscle, Skeletal, Mice, Myostatin, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myostatin and Sarcopenia: Opportunities and Challenges - A Mini-Review. https://app.cochat.ai/papers/10.1159/000356740
- The paper
- White, T. A., & LeBrasseur, N. K. (2014). Myostatin and Sarcopenia: Opportunities and Challenges - A Mini-Review. Gerontology. https://doi.org/10.1159/000356740
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.